Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101 [0.03%]
菲达尼辛：Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promisin...
Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381 [0.03%]
达塞曲匹：JTT 705；JTT-705；R 1658；R1658；RG1658；RO 4607381；RO4607381
Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This r...
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR [0.03%]
纳曲酮/布普品：康莱特(Contrave)；纳曲酮缓释片/布普品缓释片
In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and ...
John Z Duan
John Z Duan
Background and objective: Drug-drug interaction (DDI) is an important aspect of drug development, especially for safety. When a drug is used concomitantly with other drug(s), one of the major concerns is the change of exp...
Wei Wu
Wei Wu
MicroRNA (miRNA) is an endogenous non-protein coding small RNA molecule that negatively regulates gene expression by the degradation of messenger RNA (mRNA) or the suppression of mRNA translation. miRNA plays important roles in physiologic ...